

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-28 (Cancelled)

29. (Previously Presented) A method of selecting a dopaminergic neuron precursor cell, wherein the method comprises:

contacting a cell sample thought to comprise a dopaminergic neuron precursor cell with an antibody against:

- (a) a polypeptide encoded by a polynucleotide comprising a sequence selected from
 - (i) a nucleotide sequence comprising nucleotides 177 to 2280 of SEQ ID NO: 1 or nucleotides 127 to 2079 of SEQ ID NO: 2, or a sequence complementary to either of said nucleotide sequences;
 - (ii) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3 or 4, or a sequence complementary to said nucleotide sequence;
 - (iii) a nucleotide sequence encoding an amino acid sequence in which a signal sequence portion is deleted in the amino acid sequence of SEQ ID NO: 3 or 4, or a sequence complementary to said nucleotide sequence;
 - (iv) a nucleotide sequence encoding an amino acid sequence with a deletion, insertion, substitution, or addition of one or more amino acids in the amino acid sequence of SEQ ID NO: 3 or 4, or a sequence complementary to said nucleotide sequence; and,
 - (v) a nucleotide sequence that hybridizes under stringent conditions with the nucleotide sequence of (i); or
- (b) a fragment of said polypeptide comprising at least eight amino acid residues; and

selecting the dopaminergic neuron precursor cell, wherein the dopaminergic neuron precursor cell has bound to the antibody.

30. (Previously Presented) The method according to claim 29, wherein the method comprises the step of separating the dopaminergic neuron precursor cell by flow cytometry.

31. (Previously Presented) The method according to claim 29, wherein the antibody has an affinity for an extracellular region of the polypeptide.

32. (Previously Presented) A method of producing a dopaminergic neuron precursor cell, wherein the method comprises the step of contacting a cell sample thought to comprise a dopaminergic neuron precursor cell with an antibody against:

- (a) a polypeptide encoded by a polynucleotide comprising a sequence selected from
 - (i) a nucleotide sequence comprising nucleotides 177 to 2280 of SEQ ID NO: 1 or nucleotides 127 to 2079 of SEQ ID NO: 2, or a sequence complementary to either of said nucleotide sequences;
 - (ii) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3 or 4, or a sequence complementary to said nucleotide sequence;
 - (iii) a nucleotide sequence encoding an amino acid sequence in which a signal sequence portion is deleted in the amino acid sequence of SEQ ID NO: 3 or 4, or a sequence complementary to said nucleotide sequence;
 - (iv) a nucleotide sequence encoding an amino acid sequence with a deletion, insertion, substitution, or addition of one or more amino acids in the amino acid sequence of SEQ ID NO: 3 or 4, or a sequence complementary to said nucleotide sequence; and,
 - (v) a nucleotide sequence that hybridizes under stringent conditions with the nucleotide sequence of (i); or
- (b) a fragment of said polypeptide comprising at least eight amino acid residues.

33. (Previously Presented) The method according to claim 32, wherein the method comprises the step of selecting the dopaminergic neuron precursor cell, wherein the dopaminergic neuron precursor cell has bound to the antibody.

34. (Previously Presented) The method according to claim 32, wherein the method comprises the step of separating the dopaminergic neuron precursor cell by flow cytometry.

35. (Previously Presented) The method according to claim 32, wherein the antibody has an affinity for an extracellular region of the polypeptide.

36-37. (Cancelled)

38. (Previously Presented) A reagent for selecting or producing a dopaminergic neuron precursor cell, the reagent comprising an antibody against:

- (a) a polypeptide encoded by a polynucleotide comprising a sequence selected from:
 - (i) a nucleotide sequence comprising nucleotides 177 to 2280 of SEQ ID NO: 1 or nucleotides 127 to 2079 of SEQ ID NO: 2, or a sequence complementary to either of said nucleotide sequences;
 - (ii) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3 or 4, or a sequence complementary to said nucleotide sequence;
 - (iii) a nucleotide sequence encoding an amino acid sequence in which a signal sequence portion is deleted in the amino acid sequence of SEQ ID NO: 3 or 4, or a sequence complementary to said nucleotide sequence;
 - (iv) a nucleotide sequence encoding an amino acid sequence with a deletion, insertion, substitution, or addition of one or more amino acids in the amino acid sequence of SEQ ID NO: 3 or 4, or a sequence complementary to said nucleotide sequence; and,
 - (v) a nucleotide sequence that hybridizes under stringent conditions with the nucleotide sequence of (i); or

Appl. No. 10/532,264
Amdt. dated April 4, 2008
Reply to Office Action of March 5, 2008

PATENT

(b) a fragment of said polypeptide comprising at least eight amino acid residues.